Approximately 15% of breast cancers are classified as human epidermal growth factor receptor 2 (HER2)-positive (HER2^+^) \[[@CR1]\]. HER2 positivity confers an aggressive phenotype and was associated with poor long-term outcomes \[[@CR2]\] until the incorporation of HER2-targeted agents into treatment which resulted in a 50% reduction in recurrence and a 30% improvement in survival \[[@CR3], [@CR4]\].

The two most common methods for HER2 testing are immunohistochemistry (IHC) to assess protein overexpression and fluorescence in-situ hybridization (FISH) to assess gene amplification. Single-probe FISH enumerates HER2 copies per nucleus. Dual-probe FISH includes both an HER2 probe and a chromosome 17 centromere probe, providing an HER2/CEP17 ratio in addition to absolute HER2 copy number \[[@CR5]\]. Intrinsic molecular subtype analysis using gene expression profiling is not used clinically, but may better represent the inherent biologic heterogeneity of breast cancer than conventional biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and HER2 \[[@CR6], [@CR7]\]. While all intrinsic molecular subtypes have been observed among clinically HER2^+^ breast cancers defined by traditional IHC/FISH criteria, the majority (67%) are classified as HER2-enriched, with ER-positive (ER^+^)/HER2^+^ cases being HER2-enriched 54% of the time \[[@CR8]\]. In contrast, among clinically HER2-negative (HER2^--^) cases, only \~ 7% are of the HER2-enriched subtype \[[@CR9]\]. Recent data suggest that the HER2-enriched molecular subtype may be a better predictor of response to HER2-targeted therapy than IHC or FISH assessments \[[@CR10]\].

The American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) updated their HER2 testing guidelines in 2013 \[[@CR11]\]. It is now recommended that for HER2 equivocal cases (i.e., IHC 2+ or HER2 copies ≥ 4 and \< 6 and HER2/CEP17 ratio \< 2), FISH be performed using a probe for other genes on chromosome 17 to serve as the denominator to determine the HER2/chromosome 17 ratio. Genes such as retinoic acid receptor alpha (RARA), Smith-Magenis Syndrome (SMS), or tumor protein p53 (TP53) are located further away from HER2 than the centromere and are thus less likely to be co-amplified with HER2 than the centromere. Thus, an HER2/alternative chromosome 17 probe ratio of ≥ 2 may more accurately reflect HER2 gene amplification than the HER2/CEP17 ratio \[[@CR12]\].

Using the alternative probe method has resulted in an increased number of breast cancers classified as HER2-positive \[[@CR13]\]. However, whether or not these cancers have similar clinical and pathologic features or respond as well to HER2-targeted therapy as breast cancers defined as HER2-positive by traditional IHC/FISH criteria is unclear.

We identified all breast cancers at our institution since 2013 classified as HER2-positive only by the alternative probe method. We identified 31 such cases, and 20 of those had sufficient tissue for PAM50 intrinsic subtype analysis. As a comparison group, we selected 19 consecutive cases classified as HER2^+^ by traditional FISH criteria during the same period. We reviewed their clinical and pathologic features and determined intrinsic molecular subtype analysis using the PAM50 research-based assay as previously described \[[@CR14]\] (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 1Clinical and pathologic characteristics of breast cancer patients with positive HER2 alternative probePatient no.HistologyGradeER/PRHER2 IHC^a^HER2 CopiesHER2/CEP17 ratioHER2/P53 ratioHER2 FISH repeated on a 2nd tumor specimenIntrinsic subtypeTNM stageHerceptin ± chemo given?NAT, AT, METHerceptin ± chemo regimen^b^If NAT, pathologic response?Follow-up time^c^Disease status1IDC3+/++ 24.151.12.2NegativeLuminal ApT1aN0NoN/AN/AN/A16 monthsRemission2ILC2+/−+ 24.471.52.9NegativeNormalcT2N1NoNATddAC-TPR42 monthsRemission3IDC3+/++ 25.771.82.8Not doneLuminal AcT3N0YesNATTHPCR22 monthsRemission4^d^IDC3+/++ 24.91.22.8Not doneLuminal BcT1cN1YesNATddAC-THPPR16 monthsRemission5IDC2+/+0--1+4.671.52.1Pos by alt probeLuminal ApT1aN0YesATTHN/A24 monthsRemission6^e^IDC2+/++ 34.511.32.6Pos by alt probeLuminal BpT1bNxYesATTCy-HPN/A15 monthsRemission7IDLC2+/++ 24.881.53.0Pos by conventional FISH^f^Luminal ApT2N2YesATddAC-THPN/A12 monthsRemission8IDLC3+/++ 24.051.92.2Not doneLuminal ApT1cN1aYesATTCy-HN/A35 monthsRemission9IDC3+/−+ 24.621.52.7NegativeLuminal BcT1cN1aYesATTCHN/A33 monthsRemission10IDC2+/++ 25.421.52.6Not doneLuminal AcT2N1aYesATddAC-THPN/A31 monthsRemission11IDLC3+/++ 35.421.32.6Not doneLuminal BcT2N0YesATddAC-THPN/A18 monthsRemission12IDLC2+/++ 24.451.53.3NegativeLuminal ApT1bN0YesATTHN/A29 monthsRemission13IDC2+/++ 24.121.22.1NegativeLuminal AcT2N1M1bYesMETcapecitabineN/A19 monthsStable dz14IDC1+/−+ 35.931.72.8naLuminal Ananananananana15IDC3−/−0--1+5.561.22.3NegativeNScT2N0YesNATddAC-THP as NAT, capecitabine as ATPR27 monthsRemission16IDC2+/++ 35.831.63.2Not doneNSpT1bN0YesATTHN/A40 monthsRemission17IDC2+/+0--1+4.171.32.3Not doneNSpT1cN1miNoATTCyN/A26 monthsRemission18IDLC2+/++ 24.721.23.3Not doneNSpT1bN0YesATtrastuzumab and endocrine txN/A2 monthsRemission19ILC2+/++ 24.371.62.7Not doneNScTxNxM1bYesMETVarious chemo + anti-HER2 txN/A36 monthsDied of disease20ILC2+/++ 24.621.52.3naNSnanananananana21IDLC1+/++ 24.421.42.6naNSnanananananana22IDC3+/++ 24.421.62.2naNSpT2N2Mxnanananana23IDC1+/++ 24.451.62.1naNSnanananananana24IDLC3+/+0--1+4.131.52.9Not doneNSpT1cN0nananananana25IDLC3+/++ 24.681.22.5naNSnanananananana26^d^IDLC2+/+0--1+5.131.42.1Not doneLuminal ApT1cN0NoN/AN/AN/A9 monthsRemission27^d^IDLC2+/++ 24.221.73.2Positive by conventional FISH^f^Luminal ApT1bN0YesATTH ×2 weeks, then T-DM1 ×3 dosesN/A13 monthsRemission28IDC3+/++ 25.171.92.2Not doneLuminal ApT1bN0YesATTHN/A7 monthsRemission29IDC2+/++ 24.791.42.5NegativeLuminal ApT2N1aYesATddAC-THPN/A6 monthsRemission30IDC2+/++ 24.451.63.5naLuminal Bnanananananana31IDC2+/++ 35.071.32.6naLuminal Ananananananana^a^HER2 IHC: 0--1+ is negative, 2+ is equivocal, 3+ is positive^b^All patients who received trastuzumab-based treatment received trastuzumab (H) for 1 year unless otherwise specified^c^Follow up time defined as time in months from date of initial breast biopsy to date of last clinical follow-up^d^Patients with oncotype Dx score: patient 4 score 29, patient 26 score 12, patient 27 score 21^e^Patient had post-mastectomy recurrence and had history of prior ALND; so current nodal status could not be assessed^f^Repeat HER2 testing for patient 7 showed HER2 copies of 4.53 and HER2/CEP17 ratio of 2.0 and for patient 27 showed HER2 copies of 6.5 and HER2/CEP17 ratio of 2.3*AT* adjuvant therapy, *CR* complete response, *ddAC* dose-dense adriamycin + cyclophosphamide, *ER* estrogen receptor, *FISH* fluorescence in-situ hybridization, *H* herceptin (trastuzumab), *HER2* human epidermal growth factor receptor 2, *IDC* invasive ductal cancer, *IDLC* invasive cancer with ductal and lobular features, *IHC* immunohistochemistry, *ILC* invasive lobular cancer, *MET* therapy for metastatic disease, *N/A* not applicable, *na* not available, *NAT* neoadjuvant therapy, *NS* not sufficient for testing, *P* pertuzumab, *PR* partial response, *PR* progesterone receptor, *T* weekly paclitaxel ×12, *TC* taxotere (docetaxel) + carboplatin, *TCy* taxotere (docetaxel) + cyclophosphamide, *TNM* tumor node metastasis, *Tx* therapyTable 2Randomly selected consecutive HER2^+^ cases by traditional FISH criteriaPatient no.HistologyGradeER/PRHER2 IHC^a^HER2 copiesHER2/CEP17 ratioIntrinsic subtypeTNM stageHerceptin ± chemo given?NAT, AT, METHerceptin ± chemo regimen^b^If NAT, pathologic response?Follow-up time^c^Disease status1IDC3+/++ 319.15.8NSpT1cN0No; patient declinedN/AN/AN/A9 monthsRemission2IMPC2−/−+ 317.64.8NSpT1bNxNo; not offered 2/2 age/comorbiditiesN/AN/AN/A4 monthsDied of AAA rupture3IDC3+/++ 320.66.6Luminal AcT2N1M0YesNAT & ATNAT: T-DM1 + P on a trial, AT: THPPR25 monthsRemission4IDC3+/++ 3\> 105.2HER2-EcT1cN0YesNAT & ATNAT: T-DM1 + P on a trial, then AT: docetaxel ×4 cycles + H ×1 yearCR12 monthsRemission5IDC3−/−+ 3\> 201.0^d^HER2-EcT1cN0YesNATTHPCR18 monthsRemission6IDC2−/−+ 312.85.4NScT2-3 N1YesNATTHP-ddACPR5 monthsRemission7IDC3−/−+ 323.35.3HER2-EcT2N0nanaNananana8IDC3−/−+ 320.76.4NSpT1cNxYesATTHN/A27 monthsRemission9ILC2−/−+ 3\> 65.6NSpT1aN0YesATTHN/A25 monthsRemission10IDC3−/−+ 326.37.6HER2-EpT1bN0YesATTHN/A30 monthsRemission11IDC3−/−+ 3\> 10\> 3.8HER2-EpT1bN0YesATTHN/A21 monthsRemission12IMPC3−/−+ 319.857.4HER2-EpT1cN1aYesATddAC-THN/A28 monthsRemission13IDC2+/−+ 337.26.8NSpT1bN0YesATddAC-THN/A26 monthsRemission14IDC3+/−+ 36.883.2NSpT2N1aYesATTHP ×12 weeks, ddACX2 (stopped 2/2 SAE, 1 year H)N/A22 monthsRemission15IDC3+/−+ 3\> 209.5NSpT1aN0YesATT-DM1 on a trialN/A20 monthsRemission16IDC3+/−+ 3238.1HER2-EpT1bN1aYesATddAC-THPN/A17 monthsRemission17IDC3+/++ 3\> 103NST2N1M1bYesMETTHP, AC, variousN/A35 monthsAlive, on tx18IDC3−/−+ 326.79.4HER2-Enanananananana19IDC2+/−+ 320.33.4NScT3N1nananananana^a^HER2 IHC: 0--1+ is negative, 2+ is equivocal, 3+ is positive^b^All patients who received trastuzumab-based treatment received trastuzumab (H) for 1 year unless otherwise specified^c^Follow up time defined as time in months from date of initial breast biopsy to date of last clinical follow-up^d^ HER2 ratio 1.0 because HER2 copies and CEP 17 copies both \> 20, so HER2 alternative probe ratio performed to confirm HER2 status*AC* Adriamycin + cyclophosphamide, *AT* adjuvant therapy, *CR* complete response, *ddAC* dose-dense adriamycin + cyclophosphamide, *ER* estrogen receptor, *FISH* fluorescence in-situ hybridization, *H* herceptin (trastuzumab), *HER2* human epidermal growth factor receptor 2, *HER2-E* HER2-enriched, *IDC* invasive ductal cancer, *IHC* immunohistochemistry, *ILC* invasive lobular cancer, *IMPC* invasive micropapillary cancer, *MET* therapy for metastatic disease, *N/A* not applicable, *na* not available, *NAT* neoadjuvant therapy, *NS* not sufficient for testing, *P* pertuzumab, *PR* partial response, *PR* progesterone receptor, *T* weekly paclitaxel ×12, *T-DM1* ado-trastuzumab, *TNM* tumor node metastasis, *Tx* therapy

Among the 31, alternative probe-positive cases, 30 (97%) were ER^+^ and 11 (35%) were high grade. In contrast, among the 19 cases that were HER2^+^ by traditional FISH criteria, nine (47%) were ER^+^ and 14 (74%) were high grade (*p* = 0.0002). Repeat HER2 testing was performed on a second tumor sample in 11 cases and seven of those were negative for HER2 gene amplification by both traditional FISH criteria and alternative probe method. Two cases were confirmed HER2^+^ by conventional FISH and two only by the alternative probe method (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).

Adequate tissue for PAM50 intrinsic subtype analysis was available for 20 alternative probe-positive cases and nine cases that were HER2^+^ by traditional FISH criteria. None (0%) of the 20 alternative probe cancers had HER2-enriched intrinsic subtype, while eight (89%) of the nine HER2^+^ traditional controls were of the HER2-enriched molecular subtype (*p* = 0.0001).

Clinical and pathologic data for patients in the alternative probe-positive cohort is provided in Table [1](#Tab1){ref-type="table"}. Staging information was available for 24 patients. Twenty-one had early-stage disease (12 = node negative, 9 = node positive), one patient had a postmastectomy recurrence, and two patients had metastatic disease. Treatment information was available for 22 patients. Only four patients did not receive HER2-targeted therapy, one with metastatic disease and three with node-negative early-stage disease. Of the early stage patients who did receive HER2-targeted therapy, only two received it in the neoadjuvant setting, along with chemotherapy; one had a pathologic complete response (pCR) and one had partial responses (PR). Similarly, only four patients in the traditional HER2^+^ cohort received neoadjuvant HER2-targeted therapy with chemotherapy; two had a pathologic PR and two (both patients with HER2-enriched subtype) achieved pCR (Table [2](#Tab2){ref-type="table"}). Given the small number of patients treated in the neoadjuvant setting, we cannot draw meaningful conclusions regarding response to HER2-targeted therapy among the alternative probe cases.

In the alternative probe-positive cohort, when considering the early-stage patients who received concurrent chemotherapy and HER2-targeted therapy, all except one had ER^+^ tumors, eight had no nodal involvement, and five had only N1a or N1mic disease. Had these tumors been considered HER2-negative, all might have been candidates for genomic expression assays to determine the need for chemotherapy, yet only three were evaluated for such (Table [1](#Tab1){ref-type="table"}). Oncotype Dx was performed on tumors from three patients, with recurrence scores of 29, 26, and 12. The patient with the recurrence score of 12 had T1cN0 ER^+^ disease, was treated with endocrine therapy only without any chemotherapy or HER2-targeted therapy, and remains in remission at the last follow-up.

In conclusion, these findings highlight the unique pathologic and molecular characteristics of breast cancers classified as HER2^+^ only by an alternative probe method, and raise questions regarding the appropriate management of these cancers. More data regarding response of these breast cancers to HER2-targeted therapies is needed.
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